Impact of Metabolic Disturbances and Malnutrition-Inflammation on 6-Year Mortality in Japanese Patients Undergoing Hemodialysis

Therapeutic Apheresis and Dialysis

Volumn 19, Issue 1, 2015, Pages 30-39

  Nakagawa, Naoki ^a   Matsuki, Motoki ^a,b   Yao, Naoyuki ^b,c   Hirayama, Tomoya ^b   Ishida, Hironori ^b   Kikuchi, Kenjiro ^a,d   Hasebe, Naoyuki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b Kitasaito Hospital   (Japan)

^c Asahikawa Rehabilitation Hospital   (Japan)

^d Hokkaido Junkanki Hospital   (Japan)

Author keywords

End stage renal disease; Inflammatory cytokine; Malnutrition; Metabolic syndrome

Indexed keywords

ADIPONECTIN; ALBUMIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; INSULIN; NITROGEN; ORAL ANTIDIABETIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UREA;

ACUTE HEART INFARCTION; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERTENSION; JAPAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MALNUTRITION; METABOLIC DISORDER; METABOLIC SYNDROME X; MORTALITY; NUTRITIONAL STATUS; PRIORITY JOURNAL; SUBCUTANEOUS FAT; UREA NITROGEN BLOOD LEVEL; WAIST CIRCUMFERENCE; ADVERSE EFFECTS; AGE; AGED; BLOOD; CAUSE OF DEATH; COHORT ANALYSIS; INFLAMMATION; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; METABOLIC DISEASES; MIDDLE AGED; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL;

ADIPONECTIN; AGE FACTORS; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; JAPAN; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MALNUTRITION; METABOLIC DISEASES; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SEX FACTORS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922722997     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12190     Document Type: Article

References (34)

1. Isomaa B, Almgren P, Tuomi T etal. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
2. Grundy SM, Cleeman JI, Daniels SR etal. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
3. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480.
4. Peralta CA, Kurella M, Lo JC, Chertow GM. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2006;15:361-365.
5. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011;6:2364-2373.
6. Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22:198-203.
7. Westerink J, Visseren FL. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011;10:13.
8. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
9. Peake PW, Kriketos AD, Campbell LV, Shen Y, Charlesworth JA. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur J Endocrinol 2005;153:409-417.
10. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
11. Zoccali C, Mallamaci F, Tripepi G etal. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-141.
12. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008;23:2619-2628.
13. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
14. Silverberg DS, Wexler D, Blum M, Iaina A. The Cardio Renal Anemia Syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 2003;60:S93-S102.
15. Bouillanne O, Morineau G, Dupont C etal. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 2005;82:777-783.
16. Yamada K, Furuya R, Takita T etal. Simplified nutritional screening tools for patients on maintenance hemodialysis. Am J Clin Nutr 2008;87:106-113.
17. Kobayashi I, Ishimura E, Kato Y etal. Geriatric Nutritional Risk Index, a simplified nutritional screening index, is a significant predictor of mortality in chronic dialysis patients. Nephrol Dial Transplant 2010;25:3361-3365.
18. Park JH, Kim SB, Shin HS, Jung YS, Rim H. Geriatric nutritional risk index may be a significant predictor of mortality in Korean hemodialysis patients: a single center study. Ther Apher Dial 2012;16:121-126.
19. Daugirdas JT. 2nd-generation logarithmic estimates of single-pool variable volume Kt/V-an analysis of error. J Am Soc Nephrol 1993;4:1205-1213.
20. Nakagawa N, Yao N, Hirayama T etal. Potential impact of renin-angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients. Hypertens Res 2011;34:592-598.
21. Matsuzawa Y, Nakamura T, Takahashi M etal. New criteria for "obesity disease" in Japan. Circ J 2002;66:987-992.
22. Grundy SM, Cleeman JI, Merz CNB etal. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
23. Talib A, Nakagawa N, Saito E etal. The balance of fetuin-A and osteoprotegerin is independently associated with diastolic dysfunction in hemodialysis patients. Hypertens Res 2012;35:426-433.
24. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16(Suppl 1):S83-88.
25. Wang AY, Lam CW, Wang M etal. Increased circulating inflammatory proteins predict a worse prognosis with valvular calcification in end-stage renal disease: a prospective cohort study. Am J Nephrol 2008;28:647-653.
26. Tu SF, Chou YC, Sun CA, Hsueh SC, Yang T. The prevalence of metabolic syndrome and factors associated with quality of dialysis among hemodialysis patients in Southern Taiwan. Glob J Health Sci 2012;4:53-62.
27. Ucar E, Huzmeli C, Guven O etal. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions. Ren Fail 2009;31:221-228.
28. Yang SY, Chiang CK, Hsu SP etal. Metabolic syndrome predicts hospitalization in hemodialysis patients: a prospective Asian cohort study. Blood Purif 2007;25:252-259.
29. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Ilic M, Stokic E. Metabolic syndrome in HD patients: association with body composition, nutritional status, inflammation and serum iron. Intern Med 2007;46:945-951.
30. Tsangalis G, Papaconstantinou S, Kosmadakis G, Valis D, Zerefos N. Prevalence of the metabolic syndrome in hemodialysis. Int J Artif Organs 2007;30:118-123.
31. Lee CC, Lee RP, Subeq YM, Wang CH, Fang TC, Hsu BG. Fasting serum total ghrelin level inversely correlates with metabolic syndrome in hemodialysis patients. Arch Med Res 2008;39:785-790.
32. Tsai YC, Lee CT, Huang TL etal. Inflammatory marker but not adipokine predicts mortality among long-term hemodialysis patients. Mediators Inflamm 2007;2007:19891.
33. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F, Grp MS. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007;71:1279-1286.
34. Bonet J, Martinez-Castelao A, Bayes B. Metabolic syndrome in hemodialysis patients as a risk factor for new-onset diabetes mellitus after renal transplant: a prospective observational study. Diabetes Metab Syndr Obes 2013;6:339-346.